

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1430 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/531,475	04/15/2005	Dirk Inze	BJS-5547-2	1234
23117 NIXON & VA	7590 04/02/201 NDERHYE, PC	EXAMINER		
901 NORTH GLEBE ROAD, 11TH FLOOR			COLLINS, CYNTHIA E	
ARLINGTON	, VA 22203		ART UNIT	PAPER NUMBER
			1638	
			MAIL DATE	DELIVERY MODE
			04/02/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/531,475	INZE ET AL.		
Examiner	Art Unit		
Cynthia Collins	1638		

	Cynthia Collins	1638					
The MAILING DATE of this communication appe	ars on the cover sheet with the o	correspondence add	ress				
THE REPLY FILED 23 March 2010 FAILS TO PLACE THIS AF	PLICATION IN CONDITION FOR	ALLOWANCE.					
application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appe	by was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of tion, applicant must timely file one of the following replies; (1) an amendment, affidavit, or other evidence, which places t tion in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Reque tinued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time:						
 a) The period for reply expires 3 months from the mailing date 							
The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.							
Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(n).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filled is the date for purposes of determining the period of ext under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL.	ension and the corresponding amount of thortened statutory period for reply origing than three months after the mailing date	of the fee. The appropri- nally set in the final Office e of the final rejection, e	ate extension fee be action; or (2) as ven if timely filed,				
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed w AMENDMENTS 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	s of the date of a appeal. Since a				
The proposed amendment(s) filed after a final rejection, to	out prior to the date of filing a brief.	will not be entered be	cause				
 (a) ☐ They raise new issues that would require further continuous. (b) ☐ They raise the issue of new matter (see NOTE belot). (c) ☐ They are not deemed to place the application in bether. 	nsideration and/or search (see NOT w);	E below);					
appeal; and/or (d) They present additional claims without canceling a converse NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally reje	ected claims.					
4. The amendments are not in compliance with 37 CFR 1.12	21. See attached Notice of Non-Co.	mpliant Amendment (PTOI -324)				
 Applicant's reply has overcome the following rejection(s): 		npilant / mioriani (
Newly proposed or amended claim(s) would be all non-allowable claim(s).		imely filed amendmer	nt canceling the				
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is prov. The status of the claim(s) is (or will be) as follows:		be entered and an e	xplanation of				
Claim(s) allowed: Claim(s) objected to:							
Claim(s) rejected: <u>1.4.10.13.14.40.43-44.47-48</u> . Claim(s) withdrawn from consideration:							
AFFIDAVIT OR OTHER EVIDENCE							
 The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 							
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary 	vercome all rejections under appea	l and/or appellant fail	s to provide a				
 The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER 	n of the status of the claims after er	ntry is below or attach	ed.				
 The request for reconsideration has been considered bu See Continuation Sheet. 	t does NOT place the application in	condition for allowan	ce because:				
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).						

/Cynthia Collins/ Primary Examiner, Art Unit 1638 Continuation of 5. Applicant's reply has overcome the following rejection(s): The rejection of claim 1 under 35 U.S.C. 112, second paragraph; the rejection of claim 48 under 35 U.S.C. 102(b).

Continuation of 11. does NOT place the application in condition for allowance because:

Claims 1, 4, 10, 13, 40, 43-44 and 47 remain rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement, for the reasons of record. Claim 48 as currently amended is also rejected under 35 U.S.C. 112, first paragraph, for the reasons of record set forth for the rejection of claims 1, 4, 10, 13, 40, 43-44 and 47 under 35 U.S.C. 112, first paragraph, as failing to combly with the enablement requirement.

Claim 14 remains rejected under 35 U.S.C. 102(b) as being anticipated by De Veylder L. et al. (Control of proliferation, endoreduplication and differentiation by the Arabidopsis E2Fa-DPa transcription factor. EMBO J. 2002 Mar 152(16):1360-8) for the reasons of record. The amendment of claim 14 to indicate that the claimed plant is transgenic for, or transformed with, an isolated nucleic acid sequence which is at least 95% identical to SEC ID NO:1835 would overcome the rejection of claim 14.